CASE STUDY

Aggressive infantile myofibromatosis with intestinal involvement

Tristan Römer 1*, Norbert Wagner 1, Till Braunschweig 2, Robert Meyer 3, Miriam Elbracht 3, Udo Kontny 1 and Olga Moser 1

Abstract

Background: Infantile myofibromatosis (IM) is the most common cause of multiple fibrous tumors in infancy. Multicentric disease can be associated with life-threatening visceral lesions. Germline gain-of-function mutations in PDGFRB have been identified as the most common molecular defect in familial IM.

Case presentation: We here describe an infant with PDGFRB-driven IM with multiple tumors at different sites, including intestinal polyposis with hematochezia, necessitating temporary chemotherapy.

Conclusions: PDGFRB-driven IM is clinically challenging due to its fluctuating course and multiple organ involvement in the first years of life. Early molecular genetic analysis is necessary to consider tyrosine kinase inhibitor treatment in case of aggressive visceral lesions.

Keywords: Infantile myofibromatosis, PDGFRB mutation, Intestinal polyposis, Molecular targeted therapy

Background

Infantile myofibromatosis (IM) is a rare neoplastic condition with a reported incidence of 1 in 150,000 live births, but one of the most common causes of fibrous tumors in infancy [1]. It is characterized by the development of single (solitary IM) or multiple nodular masses in the soft tissues, bones, or seldom viscera (multicentric IM with or without visceral involvement) [2]. A detailed assessment including imaging procedures is necessary to document number of lesions, size of each lesion, and proximity to vital organs [3]. Diagnosis of IM can be challenging, but is usually confirmed by characteristic histologic and immunohistochemical findings [4]. Despite its general benign course with spontaneous regression during childhood, the multicentric form of IM can be life-threatening due to visceral involvement, which most often affects the cardiopulmonary and gastrointestinal system. These cases are associated with high mortality, and treatment is challenging, frequently necessitating systemic chemotherapy to prevent progressive organ damage [1, 5–7].

Activating somatic and germline point mutations in the PDGFRB gene, encoding for the PDGFRb tyrosine kinase, which is mainly expressed in cells of mesenchymal origin, are a frequent cause of sporadic or familial IM [8–10]. Activation of the PDGFRb tyrosine kinase receptor drives multiple important intracellular signal pathways, including the Ras/MAPK pathway, thus promoting cell growth and survival [11]. The mutation c.1681C>T is the most frequent PDGFRB mutation in IM and has been shown to constitutively activate the PDGFRb receptor, eventually leading to cancer development [10–12].

We here describe a familial case of infantile myofibromatosis, harboring the characteristic PDGFRB mutation c.1681C>T, with a remarkable clinical course in terms of spatial and temporal distribution of lesions, including intestinal manifestation with indication for chemotherapy. This case illustrates the challenges the clinician can be faced within the management of multicentric IM.

* Correspondence: troemer@ukaachen.de

1Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Pauwelstrasse 30, 52074 Aachen, Germany

Full list of author information is available at the end of the article

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Case presentation

Our patient is a female child that was born full-term after an uneventful pregnancy. Immediately after birth, a firm non-tender soft tissue mass beside the lumbar spine was noted. Sonographic assessment showed a well-circumscribed, vascularized soft tissue mass, measuring 3.6 × 2.8 × 1.7 cm, localized in the right paraspinal muscles. MRI at the age of 10 days demonstrated inhomogeneous T2 hyperintensity and contrast enhancement of the lesion (Fig. 1a, b), but also revealed multiple additional tumor foci in the muscles of all four extremities, each smaller than the index lesion, but with the same imaging characteristics (Fig. 1c, d). Due to malignant appearance on MRI, biopsy of the paraspinal index lesion was performed the next day. Histopathology showed spindle-shaped cell infiltration with prominent capillary vasculature and small necrotic areas, surrounded by a hyaline matrix (Fig. 1e). On immunohistochemical analysis, tumor cells stained strongly positive for WT1 (Wilms’ tumor transcription factor-1) (Fig. 1f), but largely negative for SMA and desmin. Extensive tumor vasculization was indicated by immunopositivity for CD34 (Fig. 1g), a well-established marker for diverse progenitor cells, including vascular endothelial progenitors [13]. The Ki67 index was only 1–2%, indicating low proliferative activity (Fig. 1h). Clinical and histological picture was consistent with the diagnosis of infantile myofibromatosis with hemangiopericytoma-like pattern. Because of the general benign course of such lesions, a watch-and-wait strategy with MRI every three months was initially favored.

During the following 6 months, the intramuscular lesions spontaneously regressed. However, at the age of 5 months, the child developed intermittent hematochezia with consecutive anemia (hemoglobin 79 g/l). Cow’s milk protein allergy was initially suspected, but elimination diet of the nursing mother did not lead to cessation of rectal bleedings. Colonoscopy was performed at the age of 6 months, and at least fifteen polyps were detected in the transverse, descending, and sigmoid colon, with sessile morphology and a maximum size of 1.5 cm (Fig. 2a). As no active bleeding source could be identified on endoscopy, polypectomy was not undertaken, but instead, only biopsy of three polyps was done. Histopathology and immunohistochemical pattern showed striking similarity to the initial paraspinous tumor (Fig. 2b–d).

Because of symptomatic polyposis with intermittent hematochezia and consecutive anemia, we decided to treat the child with a chemotherapeutic regimen of vincristine, actinomycin-D, and cyclophosphamide (VAC), according to the CWS guidance for non-resectable aggressive fibromatosis [14]. Each VAC course consisted of vincristine 1.5 mg/m² once weekly over 3 weeks and actinomycin-D 1.5 mg/m² and cyclophosphamide 20 mg/kg each as a single dose on day 1.

After initiation of chemotherapy, no further episodes of hematochezia could be noted. Endoscopic reassessment after three VAC courses showed a decrease in size of polyps, so we decided to continue chemotherapy. After six VAC courses, we also noted a significantly decreasing number of polyps, as well as complete remission of the intramuscular lesions, so we then decided to omit further chemotherapy. Follow-up management was supplemented by endoscopic assessments every 3 months for early detection of progressive polyposis.

Further disease course in our patient was characterized by a fluctuating picture. While intestinal polyposis was endoscopically undetectable 1 year after omission of chemotherapy, two new superficial lesions in the occipital region with a maximum size of 1 cm had emerged at the age of 15 months. These lesions were located to the tabula interna of the skull bone by means of MRI, clearly delineated from the intracranial space by the cortical bone. Two months later, while these two lesions already showed regression in size, another lesion in close proximity to the confluens sinuum, presumably also originating from the skull bone, was newly detected (Fig. 2e). Due to lack of symptomatic brain compression or sinus vein obstruction, we decided to not immediately apply any local or further systemic treatment, but instead, a close watch-and-wait strategy was pursued, with close clinical controls and MRI every 3 months, for detection of progressive tumor growth and brain compression. Fortunately, further clinical course was uneventful, and all lesions continuously regressed throughout the second year of life. Since her second birthday, no further lesions have evolved, and to the age of 5 years at the time of this report, the child has been in good health. All aforementioned lesions have further regressed, with last MRI of the head at the age of 3 years. The timeline of detection and subsequent regression of tumor manifestations in our patient is illustrated in Fig. 3.

Family history revealed that both the child’s father and one half-brother from the father’s side had spontaneously remitting subcutaneous nodules in infancy, with the half-brother being histologically diagnosed with “cutaneous leiomyoma.” In context of the positive family history and to explore the possibility of targeted therapy in case of relapse, germline genetic analysis was initiated. The characteristic missense mutation c.1681C>T in exon 12 of the PDGFRB gene (transcript ID NM_002609.3) was found in DNA of patient's lymphocytes. Segregation analysis identified the mutation in the child’s father and her half-brother as well.

Discussion and conclusions

This case of infantile myofibromatosis showed a remarkable disease course in terms of spatial and temporal distribution of lesions, necessitating chemotherapy due to
symptomatic visceral involvement. Critical lesions in our patient were located in the gastrointestinal tract leading to hematochezia and the skull with proximity to the confluens sinuum.

There are several reports of involvement of the gastrointestinal tract in IM in the literature. Its clinical manifestations most often include chronic diarrhea, poor feeding, and weight loss, but also can comprise acute
life-threatening events such as bowel obstruction, perforation, or intussusception [15–18]. Ongoing hematochezia with development of anemia, as we observed in our patient, has not been specifically mentioned as a leading symptom before in the literature. Early endoscopic assessment and treatment is warranted in this scenario to prevent further complications. Intestinal polyposis with bleeding led us to treat the child with chemotherapy, inducing a rapid clinical response with cessation of hematochezia. After six VAC courses, a marked decrease in the number of intestinal lesions could be noted on endoscopy. We considered this to reflect a chemotherapy effect, but regression of the intestinal lesions further continued after omission of chemotherapy. How chemotherapy contributed to remission of IM-associated intestinal polyposis in our case therefore remains speculative. However, due to relevant bleeding and the potential for life-threatening events, as described in cases with intestinal involvement, prompt intervention was deemed necessary.

CNS involvement is even much rarer in IM, but can lead to brain or spinal compression [19–21]. Our patient developed a tumor lesion in close proximity to the confluens sinuum. The anatomical origin of this lesion could not be clearly determined by means of MRI, but it was assumed to be rather of osseous than dural origin, as two other lesions in this region were clearly located to the tabula interna of the skull bone. However, as this lesion showed no relevant compression of the brain and could be clearly demarcated from the sinus vein system, we decided to not immediately apply any further treatment in an asymptomatic child by weighing out risks and benefit, considering potential complications of surgery and cumulative toxicities with further chemotherapy. We instead employed a watch-and-wait strategy with close MRI controls to early detect progressive tumor growth and brain compression. Fortunately, the lesion showed spontaneous regression during further assessments, and no local or further systemic treatment was necessary. However, our management surely is debatable, considering the unpredictable
growth dynamics of this critically located lesion. All in all, the clinical course in our patient impressively demonstrates how tumors in PDGFRB-driven IM arise temporally separated during the first years of life, with each lesion showing individual growth characteristics. Growth and regression of tumors can occur simultaneously in various tissues during this vulnerable period. However, tumor development and growth seems not to be strictly restricted to early childhood, as there are reports of adolescents and young adults with PDGFRB-driven IM, in whom tumor manifestations recurred or first occurred at a later age [21–23]. Al Qawahmed et al. reported intracranial tumor growth in an adolescent girl with PDGFRB-driven IM [21]. Another report described a female with recurrence of tumor manifestations at the age of 24 years during pregnancy [22]. These reports suggest that hormonal influences during puberty or pregnancy might play a role in the initiation of tumor growth on the background of an activating PDGFRB germ-line mutation. However, molecular mechanisms triggering tissue- and age-specific tumor growth, regression, or recurrence in PDGFRB-driven IM largely remain obscure to date. At the time when diagnostic and treatment decisions had to be made in our patient, no specific guidelines existed to support decision-making, so management was mainly based on the individual clinical course. Recently, expert recommendations for the diagnosis and surveillance of patients with IM were published [24]. As all tumor manifestations in our patient showed regression throughout the second year of life, and no further symptomatic lesions evolved after the child’s second birthday, we discontinued regular sonographic and MRI assessments thereafter. Last whole body MRI at the age of 17 months and last MRI of the head at the age of 41 months also showed residual changes near the confluens sinuum, so these two lesions had not completely disappeared to the date of last MRI.
affect children. In one study, PDGFRB mutations were found in 9/15 children less than 2 years of age with multicentric IM, but not in adults with solitary myofibroma. It has therefore been proposed that PDGFRB-driven multicentric IM should be seen as a distinct entity of soft-tissue neoplasms in childhood [25]. We found the characteristic point mutation c.1681C>T in exon 12 of the PDGFRB gene, leading to the substitution of arginine to cysteine at codon 561 (p.Arg561Cys). This mutation has been found recurrently in cases of familial IM. In fact, 17 out of 21 affected families, in whom a heterozygous PDGFRB germline variant was found, were reported to carry the p.Arg561Cys variant. Clinical information is available for 19 individuals with multicentric disease from these 17 families [9, 18, 21–23, 26, 27]. To compare our case with the published ones and possibly find a recurrent phenotype, we reviewed clinical data on published cases of multicentric IM, in which the p.Arg561Cys germline variant of the PDGFRB gene was detected (Table 1). Regarding morbidity during early childhood, extent of involved anatomic sides, and frequent regression of tumor lesions by the age of 4 years at latest, our case fits well to the ones described in the literature. However, a wide clinical spectrum ranging from asymptomatic soft tissue nodules to multiple visceral manifestations resulting in life-threatening complications can be noted, even among individuals from one family. Of particular note is the case of a neonate described by Ortiz et al., who suffered from multiple organ involvement including severe gastrointestinal complications with need for bowel resection, and who died due to cardiorespiratory failure, showing that multicentric IM is a potentially lethal condition [18]. On the other hand, many patients only develop multiple nodules of the skin or subcutaneous tissue with spontaneous regression during childhood and no further organ involvement [9]. The head-neck region seems to be a frequently involved anatomic location, and bone involvement is common [9, 18, 22, 23, 26]. Most cases are diagnosed immediately after birth or during early childhood. However, the cases described by Murray et al. and Weller et al. show that tumor development due to the PDGFRB mutation p.Arg561Cys is not restricted to childhood, but requires life-long awareness of an increased tumor risk [22, 23]. It needs to be emphasized that most reports lack detailed information on individual clinical outcomes, hampering long-term prognostication in this rare and phenotypically heterogeneous disease.

The p.Arg561Cys mutation presumably disrupts the inhibitory juxtamembrane domain of PDGFRb, leading

| Reference | Cases | Age at first presentation | Clinical manifestations | Outcome |
|-----------|-------|--------------------------|-------------------------|---------|
| [9]       | 10 individuals from 4 families | 3 weeks–4 years (indicated for 6 patients) | Multiple skin and subcutaneous myofibromas in all, orbital and supranasal mass in one patient | Spontaneous regression indicated for 5 patients, including 2 with documented remission at age 4 years, surgical excision in one patient, no further information |
| [18]      | 1 male infant | Birth | Skin, eye, bone, brain, heart, lung, and gastrointestinal involvement, intestinal obstruction and perforation, failure to thrive | Bowel resection, treatment with vinblastine and methotrexate, died in infancy due to cardiorespiratory failure |
| [21]      | 1 female adolescent | Infancy (< 24 months) | Multiple nodules in infancy, extraluminal tumor in the right posterior fossa at age 14 years | Spontaneous regression of manifestations in infancy, surgical excision of intracranial tumor |
| [22]      | 2 individuals from 1 family (mother and daughter) | Birth (both) | Multiple subcutaneous nodules in 1st year of life, spinal bone lesions, pancreas tumor at age 18 months, intracranial mass originating from temporal bone at age 10 months | Mother: spontaneous regression at age 3 years, recurrence of subcutaneous tumors at age 24 years during pregnancy. Daughter: spontaneous reduction of intracranial mass after 3 months, no information on further course |
| [23]      | 1 male adult | 19 years (age at diagnosis 34 years) | Multiple recurring cutaneous, pulmonary, cranial, intraspinal, and muscular paraspinal lesions | Sustained regression of most lesions 12 months after initiation of treatment with imatinib, multiple previous treatments (chemotherapy, surgery, stereotactic radiotherapy) |
| [26]      | 2 siblings | ♀: 5 months, ♂: birth | Two congenital nodules, multiple nodules and toe necrosis at birth, cranial tumor, and bone lesion in toe at age 11 months | ♀: surgical excision, no relapse to age 6 years, ♂: no information on further course |
| [27]      | 2 individuals from 1 family | Not indicated | Severe refractory multicentric IM in index patient, no further information on clinical manifestations, congenital splenic tumor in the other patient | Treatment of index patient with vinblastine and methotrexate, no information on further course |

Note that cases of solitary IM (2 patients) and asymptomatic mutation carriers (2 patients) are not included. Mudry et al. described a family with 2 individuals affected by multicentric IM due to the mutation p.Arg561Ser, who are also not included in this list [28].
to constitutive activation of its kinase domain. The Arg561 residue seems to have a key function for the juxtamembrane-kinase domain interaction and is the most frequently mutated residue in IM families [9, 29]. PDGFRB mutations show incomplete penetrance and variable expressivity, indicating additional genetic modifiers. These probably contribute to the marked phenotypic heterogeneity even within affected families, as noted in our case and others. Among the 17 reported families with the p.Arg561Cys mutation, two mutation carriers had solitary IM and another two carriers were completely asymptomatic [9, 18, 22, 26]. Indeed, the p.Arg561Cys mutation has been shown to only weakly activate the PDGFRb receptor in fibroblasts; hence, it has been proposed that a second hit is necessary to fully activate the receptor, leading to tumor development and probably influencing extent and aggressiveness of tumor lesions [8]. Linhares et al. reported a family in whom two siblings had multicentric IM due to the p.Arg561Cys mutation, but the mother was asymptomatic although carrying the same mutation. In both affected siblings, a second heterozygous mutation in the PTPRG gene was found, eventually leading to impaired dephosphorylation of the already hyperactivated PDGFRb receptor, further promoting intracellular signal transduction and inducing excessive cell proliferation [26]. Investigating all cases with a confirmed p.Arg561Cys mutation for additional genetic lesions modifying the PDGFRb signaling pathway would show if the PDGFRB mutation alone is sufficient to cause severe IM or if second hits are essential for emergence of the full disease phenotype. This would allow a more precise molecular classification and prognostication. To date, the unpredictable disease course of PDGFRB-driven IM due to the lack of a defined genotype-phenotype correlation poses a challenge for the clinician who always must weigh out benefits and risks of aggressive treatment. Frequent assessment of lesions by repeated imaging studies is necessary to support decision-making, which always has to involve clinical characteristics, anatomic side, and growth dynamics of each lesion.

The p.Arg561Cys mutation has shown sensitivity to different kinase inhibitors, such as imatinib and sunitinib, offering a targeted therapy approach in affected patients [12, 23, 25, 28, 30, 31]. At the time of symptomatic visceral manifestation in our patient, the underlying genetic mutation in PDGFRB was unknown, and data about TKI treatment were scarce. We therefore applied VAC chemotherapy, according to the CWS treatment guidance for non-resectable aggressive fibromatosis. The VAC chemotherapy combination has yielded good responses in the treatment of aggressive fibromatosis, including 6 cases of multicentric IM, in the CWS-96 study, but cumulative toxicities and late sequelae are a concern in the young child [32]. Less intensive regimens such as vincristine and dactinomycin without cyclophosphamide have shown similar efficacy, but with less acute and long-term toxicity [6]. Another frequently applied chemotherapy regimen is the combination of vinblastine and methotrexate [18, 27, 28, 33]. However, due to the paucity of data regarding efficacy and safety of conventional chemotherapy in IM, its use should be restricted to cases with vital endangerment. Although VAC chemotherapy was well tolerated in our patient, TKI treatment would have also been a reasonable option, given the potential for severe toxicities with conventional chemotherapy and the recent reports about the successful use of TKI in PDGFRB-driven IM [23, 28, 31]. However, side effects, such as growth deceleration, are also a concern in TKI treatment, as has been described in children with chronic myeloid leukemia [34]. Treatment with imatinib is often accompanied by gastrointestinal side effects, fatigue, muscle cramps, and renal impairment, sometimes necessitating dose reductions or treatment interruptions [23]. Furthermore, the time to clinical response to imatinib in PDGFRB-driven IM is not yet defined, and its immediate efficacy in cases with vital endangerment due to critical tumor growth is doubtful. Mudry et al. reported a child with multicentric IM due to p.Arg561Ser germline mutation in PDGFRB who showed a rapid clinical response to treatment with sunitinib after 4 weeks, but developed grade 3–4 neutropenia and one episode of severe hypoglycemia [28]. It is assumed that targeted therapy against PDGFRb as a more selective approach compares favorably to the toxicity of conventional chemotherapy, but the full spectrum of adverse effects and long-term sequelae is still not known. If TKI monotherapy is sufficient to induce and sustain full disease remission is also a matter of debate, as most reports describe combination with conventional chemotherapy or second-line use in heavily pretreated patients [23, 28]. Furthermore, the necessary duration of TKI treatment in a disease caused by a germline mutation that confers a life-long tumor risk, but shows incomplete penetrance with a highly variable clinical course, remains elusive. Therefore, PDGFRB-targeted therapy offers the opportunity for a highly personalized treatment with acceptable side effects, but many issues regarding its optimal use in IM remain unsolved to date.

In conclusion, we here describe a case of familial PDGFRB-driven IM with special emphasis on the clinical challenges associated with an aggressive and fluctuating disease course. We especially highlight the unusual visceral manifestation with intestinal polyposis, hematochezia, and consecutive anemia. The endangerment of vital structures in the first years of life due to aggressive expansion and critical location of tumor lesions is in
contrast to the further course with regression of apparently all lesions throughout childhood. The challenge is not to miss out progressive organ deterioration and need for treatment in this critical time period, but also not to lose patients thereafter, as there is ongoing risk for tumor development and recurrences. A thorough genetic investigation should early be initiated in cases of multiple fibrous tumors in infancy, as this could (1) be of diagnostic value in a histologically challenging disease and (2) offer the opportunity for molecular targeted therapy in patients with aggressive tumor expansion. Therefore, genetic counseling is nowadays of utmost importance in diagnosis, prognosis, and therapy guidance in IM. However, more data are needed to define genotype-phenotype correlations and thus help in clinical decision-making and prognostication for patients with IM tumor predisposition.

Abbreviations
CNS: Central nervous system; CWS: Cooperative Weichteilsarkom study group; IM: Infantile myofibromatosis; MR: Magnetic resonance imaging; PDGF RB: Platelet-derived growth factor receptor-beta; PTPRG: Protein tyrosine phosphatase receptor-gamma; SMA: Smooth muscle actin; Tki: Tyrosine kinase inhibitor; VAC: Vincristine, actinomycin-D, cyclophosphamide; WTI: Wilms’ tumor transcription factor-1

Acknowledgements
We thank the patient and her family for cooperation.

Authors’ contributions
All authors treated the patient and read and approved the manuscript. T.R. wrote the manuscript. R.M. and M.E. performed the genetic analysis and counseling. All authors read and approved the final manuscript.

Funding
The Publication Fund of the RWTH Aachen University funded open access publication of the article. Open Access funding enabled and organized by Projekt DEAL.

Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated or analyzed.

Declarations
Ethics approval and consent to participate
Ethics approval was not required as the patient was not involved in a clinical study.

Consent for publication
Informed consent for publication was signed by the patient’s parents.

Competing interests
The authors have no conflicts of interest to disclose.

Author details
1Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Pauwelstrasse 30, 52074 Aachen, Germany. 2Institute of Pathology, RWTH Aachen University, Aachen, Germany. 3Institute of Human Genetics, RWTH Aachen University, Aachen, Germany.

Received: 11 April 2021 Accepted: 6 June 2021
Published online: 16 June 2021

References
1. Mashiah J, Hadji-Rabia S, Dompmartin A, Harroche A, Laloum-Grynberg E, Wolter M, Amorini JC, Hamel-Tellier D, Guero S, Fraitage S, Bodemer C (2014) Infantile myofibromatosis: a series of 28 cases. J Am Acad Dermatol 71(2):264–270. https://doi.org/10.1016/j.jaad.2013.03.035
2. Parham DM (2018) Fibroblastic and myofibroblastic tumors of children: new genetic entities and new ancillary testing. F1000Res 7. F1000 Faculty Rev-1963. https://doi.org/10.12688/f1000research.16236.1
3. Sargos KM, Sheybani EF, Sheny Y, Aaranake-Christinger J, Khanna G (2016) Pediatric fibroblastic and myofibroblastic tumors: a pictorial review. Radiographics 36(4):1195–1214. https://doi.org/10.1148/rg.2016150198
4. Zhao G, Zhu M, Qin C, Liu X, Zhao X (2019) Infantile myofibromatosis: 32 patients and review of the literature. J Pediatr Hematol Oncol 42(8):495–498. https://doi.org/10.1097/MPH.0000000000001603
5. Levine E, Fréneaux P, Schleiermacher G, Brisse H, Pannier S, Teissier N, Menples B, Otbach D (2012) Risk-adapted therapy for infantile myofibromatosis in children. Pediatr Blood Cancer 59(1):115–120. https://doi.org/10.1002/pbc.23387
6. Weaver MS, Navid F, Huppmann A, Meany H, Angiolillo A (2015) Vincristine and daunorubicin in infantile myofibromatosis with a review of treatment options. J Pediatr Hematol Oncol 37(3):237–241. https://doi.org/10.1097/MPH.0000000000000286
7. Wu SY, McCavit TL, Cederberg K, Galindo RL, Leavey PJ (2015) Chemotherapy for generalized infantile myofibromatosis with visceral involvement. J Pediatr Hematol Oncol 37(5):402–405. https://doi.org/10.1097/MPH.0000000000000132
8. Arts FA, Sciot R, Brichard B, Renard M, de Rocca SA, Daghay G, Noël LA, Veljhe AI, Galant C, Debiec-Rychter M, Van Danme A, Vilkka M, Heibers R, Limaye N, Poirel HA, Demoulin JB (2017) PDGFRB gain-of-function mutations in sporadic infantile myofibromatosis. Hum Mol Genet 26(10):1801–1810. https://doi.org/10.1093/hmg/ddx081
9. Cheung YH, Gayden T, Campeau PM, LeDuc CA, Russo D, Nguyen VH, Guo J, Qi M, Guo Y, Albrecht S, Moroz B, Eldin KW, Ju JT, Schwartzentruber J, Malkin D, Berghuis AM, Emil S, Gibbs RA, Burk DL, Vanstone M, Lee BH, Orchard D, Boycott KM, Chung JW, Jakab N (2013) A recurrent PDGFRB mutation causes familial infantile myofibromatosis. Am J Hum Genet 92(6):996–1000. https://doi.org/10.1016/j.ajhg.2013.04.026
10. Martignetti JA, Tian L, Li D, Ramirez MC, Camacho-Vanegas O, Camacho SC, Guo Y, Zand DJ, Bernstein AM, Masur SK, Kim CE, Otieno FG, Hou C, Abdel-Magid N, Tweddale B, Metry D, Fournet JC, Papp E, McPherson EW, Zabel C, Vaksmann G, Monicot C, Keating J, Saleman PM, Cleveland JA, Evrmen DB, Zachai E, Hakonarson H (2013) Mutations in PDGFRB cause autosomal-dominant infantile myofibromatosis. Am J Hum Genet 92(6):1001–1007. https://doi.org/10.1016/j.ajhg.2013.04.024
11. Demoulin JB, Essahgir A (2014) PDGFRB receptor signaling networks in normal and cancer cells. Cytokine Growth Factor Rev 25(3):273–283. https://doi.org/10.1016/j.cytogfr.2014.03.003
12. Arts FA, Chand D, Pecquet C, Veljhe AI, Constantinescu S, Hallberg B, Demoulin JB (2016) PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib. Oncogene 35(25):3239–3248. https://doi.org/10.1038/onc.2015.383
13. Sidney LE, Branch MJ, Dunphy SE, Dua HS, Hopkinson A (2014) Concise review: evidence for CD34 as a common marker for diverse progenitors. Stem Cells 32(6):1380–1389. https://doi.org/10.1002/stem.1661
14. Koscielniak E, Klingebiel T, Cooperative Weichteilsarkom Studiengruppe (CWS) of the Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) (2014) CWS-Guidance for risk adapted treatment of soft tissue sarcoma and soft tissue tumours in children, adolescents, and young adults. Version 1.6.1. from 24.05.2014, Stuttgart
15. Dessanti A, Massarelli G, Bosincu L, Canu L, Noya G, Dettori G (1999) Infantile myofibromatosis in children: a histologically challenging disease. The role of genetic counseling. Acta Paediatr 88(10):1134–1140. https://doi.org/10.1111/j.1651-2227.1999.tb07441.x
16. Jones VS, Philip C, Harilal KR (2007) Infantile visceral myofibromatosis–a rare cause of neonatal intestinal obstruction. J Pediatr Surg 42(4):732–734. https://doi.org/10.1016/j.jpedsurg.2006.12.006
17. Dhall D, Frykman PK, Wang HL (2008) Colorectal infantile myofibromatosis: an unusual cause of rectal prolapse and sigmoid colonic intussusception: a case report. Cases J 1(1):397. https://doi.org/10.1186/1757-1626-1-397

18. Ortiz E, Kochhar A, Chandrasekar I (2020) Invasive myofibromatosis with visceral involvement in a term newborn: a case report. Am J Pediatr 62(2):173–177. https://doi.org/10.11688/apj.20200602.30

19. Tamburini G, Mesi M, Colosimo C Jr, Lauriola L, Giangaspero F, Di Rocco C (2003) Infantile myofibromatosis of the central nervous system. Childs Nerv Syst 19(9):650–654. https://doi.org/10.1007/s00381-003-0744-y

20. Inoue M, Tanaka S, Nakatomi H, Takayanagi S, Takahashi M, Tanaka M, Momose T, Mukasa A, Saito N (2016) Intracranial infantile myofibromatosis mimicking malignant brain tumor: a case report and literature review. World Neurosurg 93:487.e15–487.e20

21. AI Qawahmed R, Sawyer SL, Vassilyadi M, Qin W, Boycott KM, Michaud J (2019) Infantile myofibromatosis with intracranial extradural involvement and PDGFRB mutation: a case report and review of the literature. Pediatr Dev Pathol 22(3):258–264. https://doi.org/10.1177/109352661877736

22. Murray N, Hanina B, Graf N, Fu H, Mylène V, Campeau PM, Ronan A (2017) The spectrum of infantile myofibromatosis includes both non-penetration and adult recurrence. Eur J Med Genet 60(7):335–338. https://doi.org/10.1016/j.ejmg.2017.02.005

23. Weller JM, Keil VC, Gellen GH, Herrlinger U, Schafer N (2019) PDGFRB mutation-associated myofibromatosis: response to targeted therapy with imatinib. Am J Med Genet A 179(9):1895–1897. https://doi.org/10.1002/ajmg.a.61283

24. Hettmer S, Dachy G, Seitz G, Agaimy A, Duncan C, Jongmans M, Hirsch S, Hettschke L, Kordes U, de Krijger RR, Metzler M, Michaeli O, Remeike K, Rimpeter T, Russo A, Smetsers S, Sparber-Sauer M, Stutz E, Bourdeaut F, Kratz CP, Demolijn JB (2020) Genetic testing and surveillance in infantile myofibromatosis: a report from the SIOPE Host Genome Working Group. Fam Cancer. https://doi.org/10.1007/s10689-020-00204-2

25. Dachy G, de Krijger RR, Fraillet S, Théate I, Birchard B, Hoffman S, Libbrecht L, Arts FA, Bouilloud P, Vilkula M, Limaye N, Demolijn JB (2019) Association of PDGFRB mutations with pediatric myofibroma and myofibromatosis. JAMA Dermatol 155(8):946–950. https://doi.org/10.1001/jamadermatol.2019.0114

26. Linhares ND, Freire MC, Cardenas RG, Bahia M, Puzenat E, Aubin F, Pena SD (2014) Modulation of expressivity in PDGFRB-related infantile myofibromatosis: a role for PTPRG? Genet Mol Res 13(3):6287–6292. https://doi.org/10.4238/2014.August.15.11

27. Ito N, Watanabe S, Mishima H, Kinoshita A, Okada M, Moriuchi H, Yoshiura K (2019) A mutation in PDGFRB in a family with infantile myofibromatosis. Acta Med Nagasakiensia 63:49–53

28. Mudry P, Slaby O, Neradil J, Sokolata J, Melicharkova K, Rohleder O, Jezova M, Seehofnerova A, Michu E, Veseliska R, Sterba J (2017) Case report: rapid and durable response to PDGFR targeted therapy in a child with refractory multiple infantile myofibromatosis and a heterozygous germline mutation of the PDGFRB gene. BMC Cancer 17(1):119. https://doi.org/10.1186/s12885-017-3115-x

29. Hassan M, Butler E, Wilson R, Roy A, Zheng Y, Liem P, Rakheja D, Pavlick D, Young LL, Rosenzweig M, Erlitch R, Ali SM, Leavey PJ, Parsons DW, Skapek SX, Laetsch TW (2019) Novel PDGFRB rearrangement in multifocal infantile myofibromatosis is tumorigenic and sensitive to imatinib. Cold Spring Harb Mol Case Stud 5(5):a004440. https://doi.org/10.1101/mcs.a004440

30. Sramek M, Neradil J, Macigova P, Mudry P, Polaskova K, Slaby O, Noskova H, Sterba J, Veseliska R (2018) Effects of sunitinib and other kinase inhibitors on cells harboring a PDGFRB mutation associated with infantile myofibromatosis. Int J Mol Sci 19(9):E2591. https://doi.org/10.3390/ijms19092599

31. Pond D, Arts FA, Mendelsohn NJ, Demolijn JB, Schauer G, Messinger Y (2018) A patient with germ-line gain-of-function PDGFRB p.N666H mutation and marked clinical response to imatinib. Genet Med 20(1):142–149. https://doi.org/10.1038/gim.2017.104

32. Pilz P, Pilgrim TB, Bizogun G, Kniest R, Koscielniak E, Carl M, Treuner J (1999) Chemotherapy in fibromatoses of childhood and adolescence: results from the Cooperative Soft Tissue Sarcoma Study (CWS) and the Italian Cooperative Study group (ICG-AEOP). Klin Padiatr 211(4):291–295. https://doi.org/10.1055/s-2008-1043802

33. Azzam R, Abboud M, Muwakkit S, Khouny N, Saab R (2009) First-line therapy of generalized infantile myofibromatosis with low-dose vinblastine and methotrexate. Pediatr Blood Cancer 52(2):308. https://doi.org/10.1002/pbc.21797

34. Millot F, Guilhot J, Baruchel A, Petit A, Leblanc T, Bertrand Y, Mazingue F, Lutz P, Verite C, Berthou C, Galambrin C, Sirvent N, Taccouben K, Chastagner P, Ganderrner V, Reguerre Y, Coulaud M, Khatifteh T, Rialland F (2014) Growth deceleration in children treated with imatinib for chronic myeloid leukaemia. Eur J Cancer 50(18):3206–3211. https://doi.org/10.1016/j.ejca.2014.10.007

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.